{
    "nct_id": "NCT04335682",
    "official_title": "A Randomized Phase II Study of Androgen Receptor Directed Therapy on COGnitive Function in Patients Treated With Darolutamide or Enzalutamide (ARACOG)",
    "inclusion_criteria": "Key inclusion criteria include:\n\n* Histologically or cytologically confirmed adenocarcinoma of the prostate\n* Progressive disease per PCWG3 criteria with EITHER: Metastatic CRPC or non- metastatic CRPC (M0CRPC)\n\n  * For mCRPC: metastatic disease documented by standard or novel imaging techniques\n  * OR for M0CPRC: no evidence of metastatic disease on standard imaging.\n* OR mHSPC\n* Surgically or medically castrated, with testosterone levels of <50 ng/dL. If the patient is medically castrated, continuous dosing with GnRH agonist or antagonist must have been initiated at least 4 weeks prior to randomization and must be continued throughout the study.\n* Eastern Cooperative Oncology Group (ECOG) performance status â‰¤2\n* Able to complete cognitive testing and patient reported outcome surveys in English.\n* Ability to swallow study medications whole.\n* Able to provide informed consent.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}